Although significant advances have been made in the past 30 years in the understanding of HIV pathogenesis, there is still a need for development of effective antiretroviral therapy for the long-term management of HIV infection in infants, children and adults, as well as antiretroviral interventions to prevent HIV in women, who have the greatest burden of HIV in sub-Saharan Africa, children, in discordant couples, men who have sex with men and certain high risk heterosexual populations. With 1.9 million people receiving antiretroviral therapy in South Africa alone, further clinical problems related to durability of therapy, viral resistance and adverse events are emerging. Moreover, male circumcision, access to voluntary counseling and HIV testing, male and female condoms and other behavioral interventions are important components of governments' strategies to control HIV, new HIV Infections remain persistently high. Biomedical interventions are urgently required especially to protect women. Without an effective HIV vaccine, it is doubtful whether eradication of the HIV infection is feasible. TB/HIV co-infection adds significant morbidity and mortality to HIV infected infants, children and adults, and is the leading cause of death in South Africa. More potent, shorter and less toxic treatment for TB, to prevent TB, and to treat drug resistant TB are desperately needed. Our proposed KAREBELO CTU, comprises a group of internationally renowned scientists, the majority of whom are based in South Africa, are women, and come from diverse racial and ethnic backgrounds. Our eight Clinical Research Sites forming the KARABELO Clinical Trials Unit (CTU) are strategically positioned in areas of high HIV prevalence and Incidence and include informal settlements, maternity units, TB clinics and an MDR hospital, cities and migrant laborers to answer critical questions in the control and prevention of both HIV and TB. The CRSs, seven of which are in South Africa and one in Long Island, New York have capacity to address critical clinical research agendas of four selected NIAID Clinical Research networks: vaccines to prevent HIV infection; microbicides to prevent HIV infection; HIV/AIDS and HIV-associated infections in infants and maternal populations; and therapeutics for HIV/AIDS and HIV-associated infections and pathogens in adults.

Public Health Relevance

HIV and TB continue to be one of greatest threats to human health. Progress in understanding and managing HIV, although revolutionary, and translated into practice at an advanced rate, has not yet yielded an effective HIV vaccine, microbicide or cure. Similarly, despite advancements in TB management, an effective vaccine for TB remains elusive.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Germuga, Donna E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wits Health Consortium (Pty), Ltd
South Africa
Zip Code
Swindells, S; Gupta, A; Kim, S et al. (2018) Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003). Int J Tuberc Lung Dis 22:1016-1022
Dietrich, Janan J; Lazarus, Erica; Andrasik, Michele et al. (2018) Mobile Phone Questionnaires for Sexual Risk Data Collection Among Young Women in Soweto, South Africa. AIDS Behav 22:2312-2321
Ramteke, Sarah M; Shiau, Stephanie; Foca, Marc et al. (2018) Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study. J Pediatric Infect Dis Soc 7:143-150
Salazar-Austin, N; Kulich, M; Chingono, A et al. (2018) Age-Related Differences in Socio-demographic and Behavioral Determinants of HIV Testing and Counseling in HPTN 043/NIMH Project Accept. AIDS Behav 22:569-579
Thiam-Diouf, Arame; Metch, Barbara; Sharpe, Cameron et al. (2018) Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention. Vaccine 36:1235-1242
Wall, Kristin M; Rida, Wasima; Haddad, Lisa B et al. (2017) Pregnancy and HIV Disease Progression in an Early Infection Cohort from Five African Countries. Epidemiology 28:224-232
Greer, Amy E; Ou, San-San; Wilson, Ethan et al. (2017) Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052. J Acquir Immune Defic Syndr 76:388-393
Bekker, Linda-Gail; Gray, Glenda E (2017) Hope for HIV control in southern Africa: The continued quest for a vaccine. PLoS Med 14:e1002241
Riddler, Sharon A; Husnik, Marla; Ramjee, Gita et al. (2017) HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial. PLoS One 12:e0178594
Hogg, Robert; Nkala, Busisiwe; Dietrich, Janan et al. (2017) Conspiracy beliefs and knowledge about HIV origins among adolescents in Soweto, South Africa. PLoS One 12:e0165087

Showing the most recent 10 out of 58 publications